Jack A Schalken, PhD, and E. David Crawford, MD, discuss recent advances in non invasive liquid biopsies for prostate cancer, and the impact of SelectMDx. Keywords: liquid biopsies, SelectMDx, prostate cancer Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid Biopsies Summary Jack A. Schalken, PhD, provides an update on urinary-based biomarkers for prostate cancer. He explains the timeline of research and development for these biomarkers. He traces the significant advances from 2002, when researchers first proved that prostate cancer cells shed through the urine, to present day and the development comprehensive risk calculators, especially SelectMDx. The first in class urine...Read More
Jack A. Schalken, PhD
Jack A Schalken PhD (53) was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doc with Dr John T Isaacs at Johns Hopkins Hospital (Baltimore, MD). Since then he is director of urological research at the Radboud University Medical Center. In 1996 Dr Schalken was appointed as full professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).